Dr. Reddy's Laboratories Plans Semaglutide Relaunch Across Canada And Overseas Markets

Market snapshot: Dr. Reddy's Laboratories has reported Q2 revenue of ₹86.98 billion compared to ₹88.28 billion in the year-ago period (as stated in the source alert; not independently verified). Additionally, the company is preparing to relaunch its semaglutide generic portfolio across Canada and other international markets by March through its domestic CDMO partner (as stated in the source alert; not independently verified).

Data Snapshot

• Received Health Canada Notice of Compliance approval for generic semaglutide injection in April 2026
• Recognized ₹240 crore provision in Q1 FY27 due to out-of-specification active pharmaceutical ingredient batches
• Dispatched 180000 semaglutide injection pens prior to temporary commercial supply suspension

Key Takeaways

• Execution on semaglutide resolution serves as a key operational benchmark following quality-related supply delays.
• Commercial expansion across Canada and additional geographies remains central to mitigating revenue erosion from key off-patent generics.
• Partnerships with domestic CDMO providers support scalable manufacturing and batch compliance.

SAHI Perspective

Dr. Reddy's push to relaunch semaglutide highlights the importance of resolving active pharmaceutical ingredient quality specifications. Restoring commercial supply allows the firm to capture early generic market share in markets where patent exclusivity has expired.

Market Implications

Re-establishing generic semaglutide supply stabilizes export revenue expectations in complex injectables, though persistent API quality hurdles or delayed batch validation could weigh on near-term operating margins.

Trading Signals

Market Bias: Neutral

Market sentiment is balanced as operational progress on generic semaglutide relaunch is weighed against the ₹240 crore inventory provision recorded in Q1 FY27 following API quality adjustments.

Overweight: Pharmaceuticals, Contract Development and Manufacturing

Trigger Factors:

• Successful batch validation and regulatory clearance for semaglutide API
• Commercial supply resumption in Canada and target markets
• Official Q2 FY27 earnings filing confirmation on stock exchanges

Time Horizon: Near-term (0-3 months)

Industry Context

Generic semaglutide represents one of the highest-value therapeutic opportunities globally following GLP-1 patent expirations in major markets. Indian drugmakers are positioning complex formulation capabilities and CDMO partnerships to capture early volume market share.

Key Risks to Watch

• Regulatory inspection delays or further API quality out-of-specification findings.
• Heightened generic competition in key international jurisdictions leading to faster price erosion.
• Legal disputes surrounding brand trademarks or patent enforcement in overseas markets.

Recent Developments

Dr. Reddy's received Health Canada approval for generic semaglutide injection in April 2026. However, in July 2026, the company temporarily halted commercial supplies and recorded a ₹240 crore provision after detecting API impurities during production scale-up.

Closing Insight

Navigating complex peptide scale-up remains pivotal for Dr. Reddy's long-term earnings trajectory as key blockbusters face patent cliffs.

High Performance Trading with SAHI.